Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Harper75on Nov 23, 2022 4:32pm
220 Views
Post# 35123277

Webinar - 10,000 foot level notes

Webinar - 10,000 foot level notesI had a couple of take-aways from the webinar.  Some previously mentioned on this board - apologies for duplicates (or if I misheard Dan).  I personally find this preso difficult to listen to.  Was he being a bit cagey or perhaps just not his best delivery?  IDK points I took from Dan's presentation...
  • Previous liver issue is now a risk greatly minimized to the point of Antibe being at the lowest risk point in development history.  They understand the problem now and new formula regime for accute will not present the same "free lunch" to the liiver...etc
  • IBD candidate to be announced within weeks
  • Phase II BU data will be available for their goal of renewed Partnering discussions (Summer 2023)
  • By Summer 2023 Dan expects to still have 2 years financial runway.
  • Pursuing Institutional Investors tabled early/mid 2023
As an existing investor, good news story.  If I were new to the Antibe story, I would probably take a look at the track record and maybe dip a toe in the water while waiting for further proof in 2023.  

Head back in the sand for a spell....
<< Previous
Bullboard Posts
Next >>